IN8bio, Inc. (INAB) Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IN8bio, Inc. on June 4, 2025, reporting events occurring on June 3, 2025. The Company, incorporated in Delaware and listed on The Nasdaq Capital Market under the symbol "INAB," is an emerging growth company. The filing details a material modification to the rights of security holders via a reverse stock split.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only quantitative data provided relates to share counts:
- Shares Outstanding (Pre-Split): 103,327,028 shares as of June 2, 2025.
- Shares Outstanding (Post-Split): Approximately 3,444,234 shares immediately following the split.
- Split Ratio: 1-for-30.
Material Changes
The primary material change is the implementation of a 1-for-30 reverse stock split, authorized by stockholders on May 8, 2025, and effective at 5:00 p.m. Eastern Time on June 5, 2025. Key impacts include:
- Every 30 shares of issued and outstanding common stock are converted into one share.
- Proportionate adjustments to the exercise price and share count for all outstanding stock options and warrants.
- Proportionate reduction in shares reserved under the 2023 Equity Incentive Plan and 2020 Employee Stock Purchase Plan.
- Issuance of cash in lieu of fractional shares; no fractional shares will be issued.
- Trading on a split-adjusted basis commences on June 6, 2025, under new CUSIP number 45674E208.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors beyond the mechanics of the stock split. The document notes that the split will not affect any stockholder's percentage ownership, except where fractional shares are cashed out.
Investor Verification Checklist
- Verify the new CUSIP number (45674E208) for trading purposes starting June 6, 2025.
- Confirm the adjusted exercise prices and share counts for any held options or warrants.
- Check for cash payments in lieu of fractional shares if holding a number of shares not divisible by 30.
- Review the Company's 10-K or 10-Q filings for the most recent financial performance data, as this 8-K does not contain financial statements.